#Canada #Toronto #Cancer Treatment #Apotex #LOQTORZI

Apotex's LOQTORZI® Gains Health Canada Approval

On October 23, 2025, news broke from Toronto that Apotex Inc., Canada’s largest pharmaceutical company, has secured a crucial Notice of Compliance (NOC) from Health Canada for its innovative treatment, LOQTORZI® (toripalimab). This significant achievement marks LOQTORZI® as the first immuno-therapy available for patients suffering from recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC), a particularly rare and aggressive form of cancer.

A Groundbreaking Treatment

The approval signifies a transformative advancement in the field of oncology for nasopharyngeal cancer, which has remained challenging to treat. LOQTORZI® is indicated for use in combination with cisplatin and gemcitabine for adults facing metastatic NPC or as a standalone treatment for those who have not responded to platinum-based therapies. This dual application showcases the versatility of LOQTORZI® in catering to various patient needs.

In a statement regarding this accomplishment, Allan Oberman, President and CEO of Apotex, articulated the company’s dedication to Canadian healthcare, saying, "LOQTORZI exemplifies our commitment to Canadian patients and the healthcare system. As the first and only Health Canada-approved immuno-therapy for this unique cancer, it delivers a transformative therapy where none previously existed, addressing a critical unmet need."

Health professionals have voiced their support for LOQTORZI®'s introduction into Canada. Dr. Nathaniel Bouganim, a medical oncologist at McGill University Health Centre, highlighted, "The availability of LOQTORZI in Canada is a meaningful step forward for patients diagnosed with nasopharyngeal carcinoma. Having this therapy accessible through a Canadian-based pharmaceutical company like Apotex helps promote equitable care for those facing this rare disease."

A Commitment to Innovation

The approval of LOQTORZI® represents Apotex's first foray into novel biologic therapies, emphasizing its ongoing commitment to enhancing treatment options for various forms of cancer. Securing Canadian rights for LOQTORZI® involved a strategic agreement with Coherus BioSciences, further embedding Apotex's position as a leading force in healthcare innovation.

Apotex, dedicated to improving everyday access to vital medicines, continues to advance its strategic vision by expanding its portfolio of pharmaceutical and healthcare products while ensuring that critical medications are accessible to all. Allan Oberman added, "As a Force for Health, Apotex is committed to building upon its strategic vision in pharmaceutical development and consumer health, working tirelessly to ensure every patient receives the care they need."

Conclusion

With the approval of LOQTORZI®, Apotex elevates the standard of care for nasopharyngeal carcinoma patients in Canada, bringing new hope and an effective treatment option to a community that has long faced challenges in managing this cancer. As Apotex continues to lead innovations in oncology, the global health landscape is set to witness transformative changes that could benefit millions.

For further details regarding LOQTORZI®, including prescribing information, precautions, and contraindications, please refer to the product monograph available at Health Canada PDF.

About Apotex

Apotex is a globally recognized Canadian-based health company committed to advancing the accessibility of innovative medicines and health products. Headquartered in Toronto, the organization prides itself on its broad portfolio that spans generic, biosimilar, and branded pharmaceuticals. With a strong focus on patient care, Apotex continues to serve as a reliable health partner across the Americas, ensuring critical medications are within reach for those in need. For more information, visit Apotex's official website.